"Business is just another form of activism," said Privateer Holdings CEO Brendan Kennedy.
Famously backed by Peter Thiel’s Founder’s Fund, this private equity firm became the first in the cannabis business to cross the $100 million mark in fundraising as it closed a $40 million round last year. Since its founding in 2010, Privateer has raised $122 million. Its portfolio includes medical marijuana producer Tilray, Bob Marley’s marijuana brand Marley Natural and Leafly, often called the ‘Yelp’ of the pot world.
BUSINESS INSIDER AUSTRALIA
The Victorian government has taken advantage of new federal laws for importing medicinal cannabis to fast-track the medicine for 29 critically ill children. The cannabidiol oral solution made by Canadian company Tilray arrived in Melbourne late last week after premier Daniel Andrews signed off on his government buying it.
CANADIAN MEDICAL ASSOCIATION JOURNAL NEWS
Some cannabis producers are funding research on pain management to fill the void, including British Columbia-based Tilray. The company funded a survey recently published in the International Journal of Drug Policy on substituting cannabis for prescription opioids and other substances. “There is a growing amount of evidence suggesting that cannabis is a safer substitute for many prescription drugs, particularly opioids,” said Philippe Lucas, vice president of patient research and access at Tilray. “Increasing the understanding and acceptance of medical cannabis as a relatively safe and effective treatment for chronic pain and other conditions could reduce the medical community’s dependence on opioids."
A Canadian company will begin exporting medicinal cannabis to Auckland's Middlemore Hospital from later this month. Tilray has been granted approvals to export oils containing THC and cannabidiol to New Zealand.
THE AGE (AUSTRALIA)
The scale of the importation, which has cost the state about $1 million to supply 29 families for a year, is the largest yet in Australia, Victorian Health Minister Jill Hennessy said.
Researchers polled 271 Tilray patients and found that 53 percent were using cannabis for pain. About 15 percent were using it to treat mental-health issues like eating disorders or post-traumatic stress disorder. Of those who reported having kicked pharmaceutical drugs for cannabis, 32 percent made the change from opioids, 16 percent from benzodiazepines and 12 percent from anti-depressants.
THE BENDIGO ADVERTISER
The state government has imported cannabidiol products from Canada in an attempt to “fast-track” treatment for 29 critically ill Victorian children. A limited amount of the cannabidiol oral solution, manufactured by Canadian company Tilray, will be available for nominated children with the most severe symptoms of intractable epilepsy.
Leafly preferred to go with ginger cannabis syrup and honey when it made a bourbon-based tipple.
The most common reason for the switch was fewer adverse side-effects, says Philippe Lucas, graduate researcher at the Centre for Addictions Research of British Columbia, a lead on the study and vice-president of patient advocacy at Tilray, the medical cannabis production and research company that funded the study. The next most common reasons were patients feeling that cannabis is safer and experiencing better symptom management.
THE GLOBE AND MAIL
The study of 271 Tilray patients found 53 per cent were using the drug for pain, with the next most common reason being the treatment of mental-health issues, such as eating disorders or post-traumatic stress disorder, at 15 per cent. Of those who claimed they had dropped pharmaceutical drugs for cannabis, 32 per cent switched from opioids; 16 per cent from benzodiazepines and 12 per cent from anti-depressants.
The study, published in the International Journal of Drug Policy, was funded by Tilray, a federally authorized medical cannabis production and research company.
UNITED PRESS INTERNATIONAL
Researchers studied more than 250 patients registered to purchase cannabis from Tilray, a federally licensed producer, with prescribed medical cannabis for the treatment of chronic pain, mental health and gastrointestinal issues. Participants responded to an online survey on cannabis use.
Study lead Philippe Lucas is vice-president of Patient Research and Access at Tilray, a federally authorized medical cannabis production and research company, and a graduate fellow at the University of Victoria Centre for Addictions Research of BC. Lucas suggests the main reasons for the switch to cannabis from prescribed meds is due to reduced side effects, better symptom management and a feeling that cannabis is safer than prescription drugs.
LOS ANGELES TIMES
Designs by the longtime friend of Marley appear on the glass jars of Marley Natural’s Anniversary Herb Collection available starting this weekend. As the art director for the Tuff Gong record label, Garrick was the man behind the look of many Bob Marley and the Wailers albums, “Rastaman Vibration,” “Exodus,” “Kaya” and “Survival” among them.
The reggae music legend’s official cannabis brand, Marley Natural, celebrates its first year in existence with the release of the Anniversary Herb Collection, featuring four boutique strains with artwork and packaging designed by Marley’s art director, Neville Garrick.